Tirzepatide 60mg

Tirzepatide 60mg is preserved in a sterile, pharmaceutical-grade borosilicate glass vial, sealed with a high-grade butyl rubber stopper and aluminum crimp to ensure long-term stability. The peptide is highly sensitive to temperature fluctuations and must be stored under controlled refrigerated conditions between 2°C and 8°C (36°F to 46°F). These conditions safeguard the molecular integrity, sterility, and potency of the formulation throughout its shelf life.

Freezing the product is strictly contraindicated, as ice crystal formation and molecular stress can irreversibly compromise the peptide’s tertiary structure. Once removed from refrigeration, tirzepatide may remain at controlled room temperature (≤25°C / 77°F) for no longer than 24 hours. Beyond this limit, degradation risks increase and the product should be discarded if unused.

Protection from direct sunlight, fluorescent light, or heat sources is mandatory, as ultraviolet exposure and thermal stress accelerate peptide denaturation and loss of bioactivity. To avoid temperature shock, the vial should only be removed from refrigeration immediately before reconstitution or administration. Once reconstituted, microbial safety dictates that the solution be stored refrigerated, and any unused portion should be discarded after 30 days.

Tirzepatide is a dual incretin receptor agonist designed as a synthetic single-chain polypeptide with a C20 fatty diacid moiety covalently attached via a linker. This structural modification confers strong albumin binding, which extends its half-life to approximately 120 hours, enabling once-weekly dosing.

The active bioagent, tirzepatide, mimics endogenous incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Through this dual receptor interaction, tirzepatide enhances glucose-dependent insulin secretion, reduces inappropriate glucagon release, delays gastric emptying, and increases satiety.

In addition to the peptide backbone, pharmaceutical formulations typically contain excipients such as:

• Sodium phosphate buffer – ensures optimal pH stability during storage.

• Citric acid monohydrate – enhances peptide solubility and stability.

• Sodium chloride – maintains isotonicity for parenteral use.

• Polysorbate 80 – prevents peptide aggregation and surface adsorption.

• Water for Injection (WFI) – sterile solvent, free from pyrogens.

  
  

All excipients are pharmaceutical-grade, validated for biocompatibility, and undergo stringent quality control. Together, they maintain formulation integrity, solubility, and stability, ensuring the peptide remains active and safe for administration.

Tirzepatide 60mg is manufactured under Good Manufacturing Practices (GMP) in pharmaceutical-grade facilities that adhere to international quality regulations. Each batch undergoes High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS/MS) to confirm molecular weight, amino acid sequence fidelity, and purity greater than 99%. Endotoxin levels are strictly monitored and maintained below pharmacopeia thresholds to ensure safety.

The peptide is provided as a lyophilized sterile powder, a process that removes water under controlled vacuum conditions to preserve structural stability during transport and storage. This freeze-drying also ensures that the peptide remains chemically intact until reconstitution. Excipients are all pharmaceutical grade and USP-compliant, chosen specifically for compatibility and long-term stability.

Packaging integrity is validated through sterility assurance testing, visual inspection, and leak-proof closure checks to guarantee product authenticity and prevent contamination. Each vial is individually labeled with lot number, expiration date, and QR codes for traceability, giving clinicians and researchers full transparency from synthesis to delivery.

Tirzepatide acts as a dual incretin mimetic, binding with high affinity to both GLP-1 and GIP receptors. This dual agonism enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon release, slows gastric emptying, and increases satiety. Unlike isolated GLP-1 receptor agonists, tirzepatide leverages the synergistic metabolic pathways of two incretin systems, achieving superior glycemic control and weight loss outcomes.

Pharmacokinetic studies demonstrate a half-life of ~120 hours, supporting once-weekly dosing. Its lipid conjugation provides strong albumin binding, prolonging systemic circulation. Clinical programs, including the SURPASS Phase 3 trials, have shown that tirzepatide induces up to 22% body weight loss in obese participants, with superior HbA1c reduction compared to semaglutide.

The safety profile remains favorable, with gastrointestinal events (nausea, vomiting, diarrhea) as the most frequently observed adverse effects, typically mild-to-moderate and transient. No significant increase in cardiovascular risk was observed in interim analyses.